Metformin + saxagliptin for type 2 diabetes

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

(2013) Wendy L. Bennett et al.   ANNALS OF INTERNAL MEDICINE

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors

(2011) Sherwyn L. Schwartz   American Journal Geriatric Pharmacotherapy

Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetes

(2011) J.-F. Gautier et al.   ANNALES D ENDOCRINOLOGIE

Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects

(2011) David W. Boulton et al.   CLINICAL DRUG INVESTIGATION

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

(2011) David W. Boulton et al.   CLINICAL PHARMACOKINETICS

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

(2011) Jean Doucet et al.   CURRENT MEDICAL RESEARCH AND OPINION

Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency

(2011) K. J. Lipska et al.   DIABETES CARE

Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks

(2011) A. Pfützner et al.   DIABETES OBESITY & METABOLISM

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

(2011) M. Nowicki et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial

(2011) Wenying Yang et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

A review of gliptins in 2011

(2011) André J Scheen   EXPERT OPINION ON PHARMACOTHERAPY

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

(2011) R. Pratley et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

(2011) M. Nowicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes

(2011) Giuseppe Derosa et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1

(2010) E M Migoya et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Standards of Medical Care in Diabetes--2011

(2010)   DIABETES CARE

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

(2010) André J. Scheen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Add-on therapies to metformin for type 2 diabetes

(2010) Mansur Shomali   EXPERT OPINION ON PHARMACOTHERAPY

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

(2010) B. Göke et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

(2010) Richard M Bergenstal et al.   LANCET

Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors

(2010) Priscilla A. Hollander et al.   POSTGRADUATE MEDICINE

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

(2009) R. A. DeFronzo et al.   DIABETES CARE

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

(2009) M. Jadzinsky et al.   DIABETES OBESITY & METABOLISM

Fixed-dose single tablet antidiabetic combinations

(2009) C. J. Bailey et al.   DIABETES OBESITY & METABOLISM

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire?

(2009) P. C. Butler et al.   DIABETOLOGIA

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials

(2009) M. Monami et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

(2008) Ralph A. DeFronzo et al.   CURRENT MEDICAL RESEARCH AND OPINION

Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

(2008) D. M. Nathan et al.   DIABETOLOGIA